Tuesday, December 12, 2006

anti cancer

SUTENT's activity against hard-to-treat tumors, particularly GIST and mRCC, both potentially life-threatening and with few, if any, other options," said Dr. John LaMattina, Pfizer president of worldwide research and development.

SUTENT is a highly selective, multi-targeted tyrosine kinase inhibitor that starves tumors of blood and nutrients needed for growth and simultaneously kills cancer cells that make up tumors.

1 Comments:

Blogger naniecheng said...

hello Dr Chong.

nana here. Came to your blog through my dad's.

Have a blessed Christmas!

5:36 PM

 

Post a Comment

<< Home